Zheng Ying, Vdovichenko Natalia, Schürmann Peter, Ramachandran Dhanya, Geffers Robert, Speith Lisa-Marie, Bogdanova Natalia, Enßen Julia, Dubrowinskaja Natalia, Yugay Tatyana, Yessimsiitova Zura Berkutovna, Turmanov Nurzhan, Hillemanns Peter, Dörk Thilo
Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Genome Analytics, Helmholtz Center for Infection Research, Braunschweig, Germany.
Int J Cancer. 2025 Feb 15;156(4):764-775. doi: 10.1002/ijc.35215. Epub 2024 Oct 14.
Endometrial cancer has been associated with pathogenic variants in mismatch repair (MMR) genes, especially in the context of the hereditary Lynch Syndrome. More recently, pathogenic variants in genes of homology-directed repair (HDR) have also been suggested to contribute to a subset of endometrial cancers. In the present hospital-based study, we investigated the relative distribution of pathogenic MMR or HDR gene variants in a series of 342 endometrial cancer patients from the Oncology Clinic in Almaty, Kazakhstan. In comparison, we also sequenced 178 breast cancer patients from the same population with the same gene panel. Identified variants were classified according to ClinVar, ESM1b, and AlphaMissense prediction tools. We found 10 endometrial cancer patients (2.9%) carrying pathogenic or likely pathogenic variants in MMR genes (7 MSH6, 1 MSH2, 2 MUTYH), while 14 endometrial cancer patients (4.1%) carried pathogenic variants in HDR genes (4 BRCA2, 3 BRCA1, 3 FANCM, 2 SLX4, 1 BARD1, 1 BRIP1). In the breast cancer series, we found 8 carriers (4.5%) of pathogenic or likely pathogenic variants in MMR genes (2 MSH2, 2 MSH6, 4 MUTYH) while 12 patients (6.7%) harbored pathogenic or likely pathogenic HDR gene variants (5 BRCA1, 3 BRCA2, 1 BRIP1, 1 ERRC4, 1 FANCM, 1 SLX4). One patient who developed breast cancer first and endometrial cancer later carried a novel frameshift variant in MSH6. Our results indicate that MMR and HDR gene variants with predicted pathogenicity occur at substantial frequencies in both breast and endometrial cancer patients from the Kazakh population.
子宫内膜癌与错配修复(MMR)基因的致病变异有关,尤其是在遗传性林奇综合征的背景下。最近,同源定向修复(HDR)基因的致病变异也被认为与一部分子宫内膜癌有关。在本项基于医院的研究中,我们调查了哈萨克斯坦阿拉木图肿瘤诊所的342例子宫内膜癌患者中致病MMR或HDR基因变异的相对分布情况。作为对照,我们还使用相同的基因检测板对来自同一人群的178例乳腺癌患者进行了测序。根据ClinVar、ESM1b和AlphaMissense预测工具对鉴定出的变异进行分类。我们发现10例子宫内膜癌患者(2.9%)携带MMR基因的致病或可能致病变异(7例MSH6、1例MSH2、2例MUTYH),而14例子宫内膜癌患者(4.1%)携带HDR基因的致病变异(4例BRCA2、3例BRCA1、3例FANCM、2例SLX4、1例BARD1、1例BRIP1)。在乳腺癌组中,我们发现8例(4.5%)携带MMR基因的致病或可能致病变异(2例MSH2、2例MSH6、4例MUTYH),而12例患者(6.7%)携带致病或可能致病的HDR基因变异(5例BRCA1、3例BRCA2、1例BRIP1、1例ERRC4、1例FANCM、1例SLX4)。一名先患乳腺癌后患子宫内膜癌的患者在MSH6基因中携带一种新的移码变异。我们的结果表明,具有预测致病性的MMR和HDR基因变异在哈萨克族乳腺癌和子宫内膜癌患者中均有相当高的发生率。